Goldman Sachs
TCRX icon

Goldman Sachs’s TScan Therapeutics TCRX Stock Holding History

Goldman Sachs’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6K Sell
37,267
-49,636
-57% -$53K ﹤0.01% 6319
2025
Q4 		$86.9K Sell
86,903
-44,077
-34% -$63.8K ﹤0.01% 6216
2025
Q3 		$238K Sell
130,980
-299,090
-70% -$530K ﹤0.01% 5875
2025
Q2 		$624K Buy
430,070
+259,721
+152% +$375K ﹤0.01% 5030
2025
Q1 		$235K Buy
170,349
+9,676
+6% +$20.9K ﹤0.01% 5571
2024
Q4 		$488K Buy
160,673
+2,049
+1% +$9.29K ﹤0.01% 5263
2024
Q3 		$790K Buy
158,624
+123,356
+350% +$744K ﹤0.01% 4798
2024
Q2 		$206K Sell
35,268
-224,880
-86% -$1.77M ﹤0.01% 5255
2024
Q1 		$2.07M Buy
260,148
+229,863
+759% +$1.45M ﹤0.01% 3843
2023
Q4 		$177K Buy
+30,285
New +$139K ﹤0.01% 5192
2021
Q4 		– Sell
-11,531
Closed -$96K – 6701
2021
Q3 		$96K Buy
+11,531
New +$107K ﹤0.01% 5921

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Goldman Sachs's TCRX Position: Q1 2026 in Review

Goldman Sachs reduced its TScan Therapeutics (TCRX) stake by 57% in Q1 2026, selling an estimated $53K and leaving 37,267 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6319.

Goldman Sachs first reported a position in TCRX in Q3 2021 and has held it in 11 quarters since. The position peaked at $2.07M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Goldman Sachs held 37,267 shares of TScan Therapeutics worth $37.6K as of Q1 2026.
  • Goldman Sachs sold 49,636 TScan Therapeutics shares in Q1 2026, an estimated $53K.
  • TScan Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6319 holding.
  • Goldman Sachs first reported a position in TScan Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • Goldman Sachs's TScan Therapeutics position peaked at $2.07M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.